雷公藤多甙联合血管紧张素受体拮抗剂治疗中等量蛋白尿IgA肾病疗效研究

发布时间：2018-04-14 11:22

本文选题：雷公藤多甙 + 血管紧张素受体拮抗剂　；参考：《中国实用内科杂志》2017年06期

【摘要】：目的比较雷公藤多甙联合血管紧张素受体拮抗剂(ARB)与单独应用ARB治疗中等量蛋白尿IgA肾病的疗效。方法纳入2014年1月至2015年12月期间于中国医科大学附属第一医院肾内科住院治疗的原发性IgA肾病患者,24 h尿蛋白定量为1.0~3.5 g,且肾功能正常,行雷公藤多甙联合ARB治疗者30例,同时选取同时期ARB单独治疗者30例为对照组。比较两组治疗前后临床指标以及两组间的临床缓解率。结果两组患者的一般临床病理特征比较差异无统计学意义。两组患者经6个月治疗后尿蛋白、血清白蛋白均明显改善(P均0.05),肾功能稳定。联合治疗组临床缓解率明显高于ARB治疗组(P0.05)。结论雷公藤多甙联合ARB能明显减少中等量蛋白尿IgA肾病患者的蛋白尿,改善血清白蛋白水平,稳定肾功能。
[Abstract]:Objective to compare the efficacy of tripterygium wilfordii and angiotensin receptor antagonist (ARB) in the treatment of moderate proteinuria IgA nephropathy.Methods from January 2014 to December 2015, 30 patients with primary IgA nephropathy were treated with tripterygium wilfordii polyglycoside combined with ARB.At the same time, 30 patients treated with ARB alone at the same time were selected as the control group.The clinical indexes before and after treatment and the clinical remission rate between the two groups were compared.Results there was no significant difference in general clinicopathological features between the two groups.After 6 months of treatment, urinary protein and serum albumin were significantly improved in both groups (P < 0.05) and renal function was stable.The clinical remission rate in the combined treatment group was significantly higher than that in the ARB treatment group (P 0.05).Conclusion Tripterygium wilfordii combined with ARB can significantly reduce proteinuria, improve serum albumin level and stabilize renal function in patients with moderate proteinuria IgA nephropathy.
【作者单位】：中国医科大学附属第一医院肾内科;
【基金】：国家自然科学基金(81500525) 辽宁省自然科学基金(2014021046)
【分类号】：R692.31

【参考文献】